HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, a major milestone in ongoing pre-clinical trials of the HeartPoint Global Implant System (HPGS) in Israel.
Following three successful rounds of pre-clinical testing where the HPGS was both successfully and uniquely placed in the main pulmonary artery and blood flow was further adjusted after the initial implantation, the most recent trial explored the placement of the minimally invasive HPGS in the arterial branches.
This innovative placement resulted in a septum shift and a reaction in the tricuspid valve, indicating that left heart diseases can also be treated with an HPGS intervention in the arterial branches.
"It is encouraging to see that our Implant System has seen significant results in pre-clinical testing, especially as we prepare for our first clinical trials," said Seth Bogner, Chairman & CEO of HeartPoint Global.
"This is a significant discovery in the treatment of life-threatening and debilitating left heart diseases. More people die from cardiovascular diseases annually than any other cause, and these successful results are an important step towards our goal of providing equitable and top-tier interventional cardiac care solutions globally."
The HPGS is a first-of-its-kind patented system of stents that allows for the adjustment of blood flow during and after placement in the main pulmonary artery and/or its branches in order to significantly improve the structure of the heart and function of the heart-lung system.
The innovative and minimally invasive intervention focuses on treating devastating left heart diseases and structural pulmonary hypertension.
Dr. David Planer, Head of Interventional Cardiology, and Dr. Gabby Elbaz-Greener, both of Hadassah Medical Center, performed the latest pre-clinical intervention in Israel.
"To put it simply, this system performs as described and is set to be a global game-changer in the treatment of cardiovascular diseases," said Prof. Dr. Paul Vogt, Head of Cardiac Surgery at Zurich University Hospital and Chairman of HeartPoint Global's Medical Advisory Board.
"This pre-clinical trial success and discovery dramatically expands the patient population and will give the interventional cardiologist more options in treating high-risk patients, including both children and adults."
Pre-clinical trials are ongoing, and clinical trials are expected to take place in Europe within the next few months.
